Abstract
Hypoxia-inducible factor (HIF) is a dimeric transcription factor identified as the major regulator of hypoxic responses in cells. Its activity is mainly regulated by protein stability. In well-oxygenated tissues prolyl hydroxylases hydroxylate HIF-1α and HIF-2α protein to provoke their proteasomal degradation. Under hypoxia the α-subunits are stabilized and dimerize with ß-subunits to constitute active transcriptional complexes. As the α-subunits are constantly translated and degraded, any interference with cellular translation will alter HIF-α expression and HIF activity. Cytokines such as interleukins or interferons as well as growth factors such as vascular endothelial growth factor or insulin-like growth factor are good examples of hormones that affect transcription, translation, or degradation of HIF-1α. In turn, HIF specific target genes also modulate the expression and/or signaling quality of cytokines or growth factors to create signal amplifying/intercepting cellular networks. We define how these signaling circuits promote or delay the progression of diseases and describe potential outcomes for patients.
Keywords: Hypoxia-inducible factor, cancer, insulin, insulin-like growth factor, interferon, interleukin, mTOR, tumor necrosis factor, vascular endothelial growth factor.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Volume: 11 Issue: 2
Author(s): Nathalie Dehne, Dominik Fuhrmann and Bernhard Brune
Affiliation:
Keywords: Hypoxia-inducible factor, cancer, insulin, insulin-like growth factor, interferon, interleukin, mTOR, tumor necrosis factor, vascular endothelial growth factor.
Abstract: Hypoxia-inducible factor (HIF) is a dimeric transcription factor identified as the major regulator of hypoxic responses in cells. Its activity is mainly regulated by protein stability. In well-oxygenated tissues prolyl hydroxylases hydroxylate HIF-1α and HIF-2α protein to provoke their proteasomal degradation. Under hypoxia the α-subunits are stabilized and dimerize with ß-subunits to constitute active transcriptional complexes. As the α-subunits are constantly translated and degraded, any interference with cellular translation will alter HIF-α expression and HIF activity. Cytokines such as interleukins or interferons as well as growth factors such as vascular endothelial growth factor or insulin-like growth factor are good examples of hormones that affect transcription, translation, or degradation of HIF-1α. In turn, HIF specific target genes also modulate the expression and/or signaling quality of cytokines or growth factors to create signal amplifying/intercepting cellular networks. We define how these signaling circuits promote or delay the progression of diseases and describe potential outcomes for patients.
Export Options
About this article
Cite this article as:
Dehne Nathalie, Fuhrmann Dominik and Brune Bernhard, Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020008
DOI https://dx.doi.org/10.2174/1871525711311020008 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Strategies to Overcome or Circumvent P-Glycoprotein Mediated Multidrug Resistance
Current Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Letters in Drug Design & Discovery Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets